Turkiye Klinikleri Journal of Sports Sciences

.: REVIEW
Akut ve Post-COVID-19'un İskelet Kası Üzerine Etkileri ve Egzersiz İntoleransı: Geleneksel Derleme
The Effects of Acute and Post-COVID-19 on Skeletal Muscle and Exercise Intolerance: Traditional Review
Zekine PÜNDÜKa
aBalıkesir Üniversitesi Spor Bilimleri Fakültesi, Antrenörlük Eğitimi Bölümü, Balıkesir, Türkiye
Turkiye Klinikleri J Sports Sci. 2023;15(3):475-82
doi: 10.5336/sportsci.2023-96715
Article Language: TR
Full Text
ÖZET
 Koronavirüse bağlı iskelet kası ile ilgili görülen semptomlar hem akut koronavirüs hastalığında [coronavirus disease-2019 (COVID19)] hem de akut sonrası sekelinde [post-acute sequelae (PASC)] yaygın olarak görülmektedir. COVID-19 hastalarında yapılan laboratuvar araştırmaları ve farklı ölçüm yöntemleriyle yapılan değerlendirmeler sonucu iskelet kas kayıplarını gösterir niteliktedir. Post-COVID kaynaklı bu kas kayıplarının ve kas hasarının mekanizması ve uzun dönemli sonuçları belirsizdir. Bu derlemede, COVID-19'un neden olduğu iskelet kası ve akut solunum sıkıntısı sendromu, kritik hastalık kas miyopatisi (kas tutulumu) ve viral yorgunluk sendromu gibi diğer fiziksel durumlarda etkilenen hücresel ve moleküler yolakları tartışmayı amaçladık. COVID-19 pandemisi sırasında, şiddetli COVID-19 ve PASC hastalarının iskelet kası zayıflığından ve egzersiz intoleransından muzdarip olduğu gözlemlendi. Histolojik araştırmalara göre oluşan kas hasarı, sitokin fırtınası, yetersiz beslenme, uzun süre inaktivite, yoğun bakımda kalma süresi, mekanik ventilasyon ve ilaç kaynaklı olduğunu gösterdi. Ayrıca sistemik inflamasyon, inaktivite, hipoksemi ve yetersiz beslenme gibi katkıda bulunan diğer faktörler de PASC'de rol oynamaktadır. Ancak PASC ile ilişkili iskelet kası zayıflığı ve egzersiz intoleransı belirsizdir. Ayrıca PASC'deki iskelet kası değişiklikleri ile kronik yorgunluk sendromu arasındaki benzerliklerin daha fazla araştırılması gerekiyor. Sonuç olarak, şiddetli düzeyde bu hastalığı geçiren ve uzun dönem tedavi gören hastalarda, hem akut dönemde hem de uzayan dönemde devam eden bu moleküller, metabolik değişiklikler iskelet kası yapısını değiştirerek kas kuvvet zayıflığına ve egzersiz intoleransına neden olabilmektedir.

Anahtar Kelimeler: COVID-19; post-COVID; iskelet kası inflamasyonu; egzersiz intoleransı
ABSTRACT
 Skeletal muscle-related symptoms associated with coronavirus are common in both acute coronavirus disease (COVID-19) and post-acute sequelae (PASC). As a result of laboratory research and evaluations made with different measurement methods in COVID-19 patients, it proves the loss of skeletal muscle fibrils. The mechanism and long-term consequences of these muscle losses and muscle damage are unclear. We aimed in this review discussed the effect of COVID-19 on the cellular and molecular pathways that are affected in skeletal muscle and other physical conditions, such as acute respiratory distress syndrome, critical illness myopathy, and post-viral fatigue syndrome. During the COVID-19 pandemic, patients with severe COVID19 and PASC suffer from skeletal muscle weakness and exercise intolerance is observed. Histological studies showed that muscle damage, cytokine storm, malnutrition, long inactivity, length of stay in intensive care, mechanical ventilation and drug-induced. Also, other contributing factors are involved in PASC, such as systemic inflammation, disuse, hypoxaemia, and malnutrition. However, the skeletal muscle weakness and exercise intolerance associated with PASC are uncertain. Also, similarities between skeletal muscle alterations in PASC and chronic fatigue syndrome need to further study. Therefore, it seems, acute COVID-19 and PASC alter skeletal muscle structure of the molecular way and it may cause muscle weakness and exercise intolerance.

Keywords: COVID-19; post-COVID; skeletal muscle inflammation; exercise intolerance
REFERENCES:
  1. World Health Organization [Internet]. [Cited: May 21, 2021]. WHO Coronavirus (COVID-19) Dashboard 2021. Available from: [Link] 
  2. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol. 2020;92(6):612-7. [Crossref]  [PubMed]  [PMC] 
  3. Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241536. [Crossref]  [PubMed]  [PMC] 
  4. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32. [Crossref]  [PubMed]  [PMC] 
  5. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-31. Erratum in: Nat Med. 2021;27(6):1116. [Crossref]  [PubMed]  [PMC] 
  6. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. [Crossref]  [PubMed]  [PMC] 
  7. Pleguezuelos E, Del Carmen A, Llorensi G, Carcole J, Casarramona P, Moreno E, et al. Severe loss of mechanical efficiency in COVID-19 patients. J Cachexia Sarcopenia Muscle. 2021;12(4):1056-63. [Crossref]  [PubMed]  [PMC] 
  8. de Andrade-Junior MC, de Salles ICD, de Brito CMM, Pastore-Junior L, Righetti RF, Yamaguti WP. Skeletal muscle wasting and function impairment in intensive care patients with severe COVID-19. Front Physiol. 2021;12:640973. [Crossref]  [PubMed]  [PMC] 
  9. Paneroni M, Simonelli C, Saleri M, Bertacchini L, Venturelli M, Troosters T, et al. Muscle strength and physical performance in patients without previous disabilities recovering from COVID-19 pneumonia. Am J Phys Med Rehabil. 2021;100(2):105-9. [Crossref]  [PubMed] 
  10. Van Aerde N, Van den Berghe G, Wilmer A, Gosselink R, Hermans G; COVID-19 Consortium. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020;46(11):2083-5. [Crossref]  [PubMed]  [PMC] 
  11. Weijs PJ, Looijaard WG, Dekker IM, Stapel SN, Girbes AR, Oudemans-van Straaten HM, et al. Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients. Crit Care. 2014;18(2):R12. [Crossref]  [PubMed]  [PMC] 
  12. Kim JW, Yoon JS, Kim EJ, Hong HL, Kwon HH, Jung CY, et al. Prognostic implication of baseline sarcopenia for length of hospital stay and survival in patients with coronavirus disease 2019. J Gerontol A Biol Sci Med Sci. 2021;76(8):e110-6. [Crossref]  [PubMed]  [PMC] 
  13. Soares MN, Eggelbusch M, Naddaf E, Gerrits KHL, van der Schaaf M, van den Borst B, et al. Skeletal muscle alterations in patients with acute Covid-19 and post-acute sequelae of Covid-19. J Cachexia Sarcopenia Muscle. 2022;13(1):11-22. [Crossref]  [PubMed]  [PMC] 
  14. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol. 1996;40(4):645-54. [Crossref]  [PubMed] 
  15. Leung TW, Wong KS, Hui AC, To KF, Lai ST, Ng WF, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol. 2005;62(7):1113-7. [Crossref]  [PubMed] 
  16. Aschman T, Schneider J, Greuel S, Meinhardt J, Streit S, Goebel HH, et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol. 2021;78(8):948-60. [Crossref]  [PubMed] 
  17. Hund E. Myopathy in critically ill patients. Crit Care Med. 1999;27(11):2544-7. [Crossref]  [PubMed] 
  18. Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature. 2021;594(7862):246-52. [Crossref]  [PubMed] 
  19. Shi A, Hillege MMG, Wüst RCI, Wu G, Jaspers RT. Synergistic short-term and long-term effects of TGF-β1 and 3 on collagen production in differentiating myoblasts. Biochem Biophys Res Commun. 2021;547:176-82. [Crossref]  [PubMed] 
  20. Shi Z, de Vries HJ, Vlaar APJ, van der Hoeven J, Boon RA, Heunks LMA, et al; Dutch COVID-19 Diaphragm Investigators. Diaphragm pathology in critically Ill patients with COVID-19 and postmortem findings from 3 medical centers. JAMA Intern Med. 2021;181(1):122-4. [Crossref]  [PubMed]  [PMC] 
  21. Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2(7):572-85. [Crossref]  [PubMed]  [PMC] 
  22. Blokland IJ, Ilbrink S, Houdijk H, Dijkstra JW, van Bennekom CAM, Fickert R, et al. [Exercise capacity after mechanical ventilation because of COVID-19: Cardiopulmonary exercise tests in clinical rehabilitation]. Ned Tijdschr Geneeskd. 2020;164:D5253. [PubMed] 
  23. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93-116. [Crossref]  [PubMed]  [PMC] 
  24. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5(1):293. [Crossref]  [PubMed]  [PMC] 
  25. Ratchford SM, Stickford JL, Province VM, Stute N, Augenreich MA, Koontz LK, et al. Vascular alterations among young adults with SARS-CoV-2. Am J Physiol Heart Circ Physiol. 2021;320(1):H404-10. [Crossref]  [PubMed]  [PMC] 
  26. Trinity JD, Craig JC, Fermoyle CC, McKenzie AI, Lewis MT, Park SH, et al. Impact of presymptomatic COVID-19 on vascular and skeletal muscle function: a case study. J Appl Physiol (1985). 2021;130(6):1961-70. [Crossref]  [PubMed]  [PMC] 
  27. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282-9. [Crossref]  [PubMed]  [PMC] 
  28. Chung HK, Ryu D, Kim KS, Chang JY, Kim YK, Yi HS, et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol. 2017;216(1):149-65. [Crossref]  [PubMed]  [PMC] 
  29. Myhre PL, Prebensen C, Strand H, Røysland R, Jonassen CM, Rangberg A, et al. Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19. Circulation. 2020;142(22):2128-37. [Crossref]  [PubMed]  [PMC] 
  30. Romanello V. The interplay between mitochondrial morphology and myomitokines in aging sarcopenia. Int J Mol Sci. 2020;22(1):91. [Crossref]  [PubMed]  [PMC] 
  31. Fujita Y, Ito M, Ohsawa I. Mitochondrial stress and GDF15 in the pathophysiology of sepsis. Arch Biochem Biophys. 2020;696:108668. [Crossref]  [PubMed] 
  32. Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax. 2015;70(3):219-28. [Crossref]  [PubMed]  [PMC] 
  33. Carré JE, Orban JC, Re L, Felsmann K, Iffert W, Bauer M, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med. 2010;182(6):745-51. [Crossref]  [PubMed]  [PMC] 
  34. Batt J, dos Santos CC, Cameron JI, Herridge MS. Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med. 2013;187(3):238-46. [Crossref]  [PubMed] 
  35. Romanello V, Sandri M. The connection between the dynamic remodeling of the mitochondrial network and the regulation of muscle mass. Cell Mol Life Sci. 2021;78(4):1305-28. [Crossref]  [PubMed]  [PMC] 
  36. Dos Santos C, Hussain SN, Mathur S, Picard M, Herridge M, Correa J, et al; MEND ICU Group; RECOVER Program Investigators; Canadian Critical Care Translational Biology Group. Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay. A Pilot Study. Am J Respir Crit Care Med. 2016;194(7):821-30. [Crossref]  [PubMed] 
  37. Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis. Eur J Clin Invest. 2021;51(1):e13429. [Crossref]  [PubMed]  [PMC] 
  38. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202(6):812-21. [Crossref]  [PubMed]  [PMC] 
  39. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. [Crossref]  [PubMed]  [PMC] 
  40. Kumar NB. Does COVID-19-related cachexia mimic cancer-related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management. J Cachexia Sarcopenia Muscle. 2021;12(2):519-22. [Crossref]  [PubMed]  [PMC] 
  41. Nagant C, Ponthieux F, Smet J, Dauby N, Doyen V, Besse-Hammer T, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis. 2020;101:342-5. [Crossref]  [PubMed]  [PMC] 
  42. Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, Caidahl K, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007;56(6):1630-7. [Crossref]  [PubMed] 
  43. Robson-Ansley PJ, de Milander L, Collins M, Noakes TD. Acute interleukin-6 administration impairs athletic performance in healthy, trained male runners. Can J Appl Physiol. 2004;29(4):411-8. [Crossref]  [PubMed] 
  44. Bach E, Nielsen RR, Vendelbo MH, Møller AB, Jessen N, Buhl M, et al. Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release. Diabetes. 2013;62(12):4023-9. [Crossref]  [PubMed]  [PMC] 
  45. Friedrich O. Critical illness myopathy: sepsis-mediated failure of the peripheral nervous system. Eur J Anaesthesiol Suppl. 2008;42:73-82. [Crossref]  [PubMed] 
  46. Remels AH, Gosker HR, Schrauwen P, Hommelberg PP, Sliwinski P, Polkey M, et al. TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J. 2010;24(12):5052-62. [Crossref]  [PubMed] 
  47. Yang X, Zeng Q, Barış M, Tezel G. Transgenic inhibition of astroglial NF-κB restrains the neuroinflammatory and neurodegenerative outcomes of experimental mouse glaucoma. J Neuroinflammation. 2020;17(1):252. [Crossref]  [PubMed]  [PMC] 
  48. Wåhlin-Larsson B, Wilkinson DJ, Strandberg E, Hosford-Donovan A, Atherton PJ, Kadi F. Mechanistic links underlying the impact of C-reactive protein on muscle mass in elderly. Cell Physiol Biochem. 2017;44(1):267-78. [Crossref]  [PubMed] 
  49. Mohammadi B, Schedel I, Graf K, Teiwes A, Hecker H, Haameijer B, et al. Role of endotoxin in the pathogenesis of critical illness polyneuropathy. J Neurol. 2008;255(2):265-72. [Crossref]  [PubMed] 
  50. Sallis R, Young DR, Tartof SY, Sallis JF, Sall J, Li Q, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021;55(19):1099-105. [Crossref]  [PubMed]  [PMC] 
  51. Marusic U, Narici M, Simunic B, Pisot R, Ritzmann R. Nonuniform loss of muscle strength and atrophy during bed rest: a systematic review. J Appl Physiol (1985). 2021;131(1):194-206. [Crossref]  [PubMed]  [PMC] 
  52. Bloch S, Polkey MI, Griffiths M, Kemp P. Molecular mechanisms of intensive care unit-acquired weakness. Eur Respir J. 2012;39(4):1000-11. [Crossref]  [PubMed] 
  53. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012;2(2):1143-211. [Crossref]  [PubMed]  [PMC] 
  54. Wierdsma NJ, Kruizenga HM, Konings LA, Krebbers D, Jorissen JR, Joosten MI, et al. Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission. Clin Nutr ESPEN. 2021;43:369-76. [Crossref]  [PubMed]  [PMC] 
  55. Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis. 2021;8:20499361211009385. [Crossref]  [PubMed]  [PMC] 
  56. Burgess LC, Venugopalan L, Badger J, Street T, Alon G, Jarvis JC, et al. Effect of neuromuscular electrical stimulation on the recovery of people with COVID-19 admitted to the intensive care unit: a narrative review. J Rehabil Med. 2021;53(3):jrm00164. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com